Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
News|Articles|June 12, 2014
Total Facility Solutions Opens Hygienic Fabrication Center
Author(s)Pharmaceutical Technology Editors
The fabrication facility will supply modular construction to the US life-science market.
Advertisement
Total Facility Solutions (TFS), a specialty contractor and services company focused on critical process infrastructure, completed the company’s first certified hygienic fabrication facility dedicated to the US life science market. Located in Burlington, North Carolina, the facility will provide hygienic and high-purity piping fabrication, stainless-steel skid fabrication, and field installations.
Off-site fabrication in a controlled environment has the benefits of cost-effectiveness and minimizing the number of people at the construction site area, which makes the site safer, notes the company. “Moving man-hours from a customer site to a regional fabrication facility helps us streamline our work,” said Joe Cestari, TFS president, in the press release. “Reducing congestion in the facility also reduces risk to safety, quality and schedule, all while meeting the stringent hygienic standards of the life science market.”
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement